Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Paracetamol Formulation 2 Clear all
Terminated Phase 2Phase 3 Interventional Results available

Paracetamol With Caffeine to Treat Episodic Tension Type Headache

NCT01755702
View directory record Official record
Conditions
Headache, Tension-Type
Interventions
Placebo, Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Pembroke Pines, Florida • Springfield, Massachusetts • Wellesley Hills, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of an Experimental Paracetamol Formulation

NCT01476176
View directory record Official record
Conditions
Headache, Tension-Type
Interventions
Experimental paracetamol, Paracetamol marketed formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT02414269
View directory record Official record
Conditions
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Genetic · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 7, 2026, 9:40 AM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

NCT01568749
View directory record Official record
Conditions
Analgesia
Interventions
Paracetamol, Paracetamol formulation 1, Paracetamol Formulation 2, Paracetamol formulation 3, Paracetamol formulation 4
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

NCT03701074
View directory record Official record
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions
Ibuprofen and acetaminophen, Ibuprofen and placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
5 Days to 21 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.

NCT01551797
View directory record Official record
Conditions
Pain
Interventions
Paracetamol 500 mg, Paracetamol 1000 mg, Paracetamol 750 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Paracetamol Formulations.

NCT01592227
View directory record Official record
Conditions
Pain
Interventions
Marketed paracetamol, Experimental paracetamol formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Terminated Phase 4 Interventional Results available

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

NCT02549716
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Stroke
Interventions
IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing

NCT02322879
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
First Treatment Period, Washout, Second Treatment Period
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®

NCT01540734
View directory record Official record
Conditions
Healthy Subjects
Interventions
Marketed paracetamol, Experimental paracetamol formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend

NCT01540721
View directory record Official record
Conditions
Healthy Subjects
Interventions
Marketed paracetamol, Experimental paracetamol formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

NCT01842633
View directory record Official record
Conditions
Pain
Interventions
Paracetamol and Caffeine, Ibuprofen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 7, 2026, 9:40 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

NCT03137017
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 7, 2026, 9:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388
View directory record Official record
Conditions
Glycogen Storage Disease Type III
Interventions
UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
Biological · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 7, 2026, 9:40 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

NCT01476189
View directory record Official record
Conditions
Healthy Subjects
Interventions
Experimental paracetamol formulation, Marketed paracetamol, Higher dose marketed paracetamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

NCT02646826
View directory record Official record
Conditions
Nocturia
Interventions
Placebo, Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
Other · Drug
Lead sponsor
Wellesley Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Brooklyn, New York • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 7, 2026, 9:40 AM EDT